Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Liver function test increased? 206 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 206 reports of Liver function test increased have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.3% of all adverse event reports for PEMBROLIZUMAB.

206
Reports of Liver function test increased with PEMBROLIZUMAB
0.3%
of all PEMBROLIZUMAB reports
24
Deaths
102
Hospitalizations

How Dangerous Is Liver function test increased From PEMBROLIZUMAB?

Of the 206 reports, 24 (11.7%) resulted in death, 102 (49.5%) required hospitalization, and 19 (9.2%) were considered life-threatening.

Is Liver function test increased Listed in the Official Label?

Yes, Liver function test increased is listed as a known adverse reaction in the official FDA drug label for PEMBROLIZUMAB.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Liver function test increased?

METHOTREXATE (3,839) ADALIMUMAB (2,070) ETANERCEPT (1,829) LEFLUNOMIDE (1,521) ABATACEPT (1,415) TOCILIZUMAB (1,406) RITUXIMAB (1,325) SULFASALAZINE (1,263) HYDROXYCHLOROQUINE (1,259) TOFACITINIB (1,221)

Which PEMBROLIZUMAB Alternatives Have Lower Liver function test increased Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Liver function test increased Reports All Drugs Causing Liver function test increased PEMBROLIZUMAB Demographics